BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

Just published, a clinical review of  38 studies comparing clinical outcomes with and without hyperthermia. Spoiler Alert, chances of complete response (no more cancer) is increased by an average of 35% when hyperthermia was added to the treatment protocol.  The studies compared included cancers of the breast, cervix, head/neck, rectum, bladder, esophagus, lung, plus superficial tumors, and melanoma. The full abstract is printed below, with links to the complete published report.

Abstract

Hyperthermia, one of the oldest forms of cancer treatment, involves selective heating of tumor tissues to temperatures ranging between 39 and 45°C. Recent developments based on the thermoradiobiological rationale of hyperthermia indicate it to be a potent radio- and chemosensitizer. This has been further corroborated through positive clinical outcomes in various tumor sites using thermoradiotherapy or thermoradiochemotherapy approaches. Moreover, being devoid of any additional significant toxicity, hyperthermia has been safely used with low or moderate doses of reirradiation for retreatment of previously treated and recurrent tumors, resulting in significant tumor regression. Recent in vitro and in vivo studies also indicate a unique immunomodulating prospect of hyperthermia, especially when combined with radiotherapy. Also, the technological advances over the last decade both in hardware and software have led to potent and even safer loco-regional hyperthermia treatment delivery, thermal treatment planning, thermal dose monitoring through noninvasive thermometry, and online adaptive temperature modulation. The review summarizes the outcomes from various clinical studies (both randomized and nonrandomized) where hyperthermia is used as a thermal sensitizer of radiotherapy and-/or chemotherapy in various solid tumors and presents an overview of the progresses in loco-regional hyperthermia. These recent developments, supported by positive clinical outcomes, should merit hyperthermia to be incorporated in the therapeutic armamentarium as a safe and an effective addendum to the existing oncological treatment modalities.

Copyright © 2015 Elsevier Ltd. All rights reserved.

Icon for Elsevier Science

“All over the map” is an American idiom for being off-topic or on a tangent. Just the opposite is true for the work we are doing here at Pyrexar Medical. Our map shows a growing number of well-respected Universities, Hospitals, and Cancer Centers, adopting hyperthermia in their cancer treatment program. Clinicians and researchers continue to publish studies demonstrating the benefit of hyperthermia when added to existing treatment protocols.

map closeup

You can see for yourself by visiting our Treatment Locations page on the website. Zoom into your target location and find out where hyperthermia treatments are being offered in your area. Click the pin and find out a little bit about the facility. With your help, we will continue to add new flags every day. Each pin represents the possibility of a new life saved by the oncology doctors and treatment staff of cancer centers around the world.

Please share our message with your social connections. PYREXAR Hyperthermia, making a difference in Cancer Care.

Meet Sam Cervantes.  Sam is a radiation therapist RT(t) at the Tacoma Valley Radiation Oncology Center in Western Washington.  The TVROC is a regional network of treatment centers made up of five locations around the Puget Sound.  Jackson Hall Medical Center in Tacoma, WA;  St. Joseph Medical Pavilion, also in Tacoma; Dr. Richard C. Ostenson Cancer Center in Puyallup; Jane Thompson Russell Cancer Care Center in Gig Harbor and Capital Medical Center in Olympia.

Sam runs the Hyperthermia equipment in the oncology department. Originally from Florida, she has been living in Washington State for the past three years. She tells us they typically use the PYREXAR BSD-500 Superficial Hyperthermia System to treat Recurrent Chest Wall tumors (breast cancer) and Head & Neck tumors in conjunction with radiotherapy.  Typically, each radiation session is accompanied by a 45-minute treatment of hyperthermia.  “We bring the treatment area up to our target temperature of 42˚F and hold that temperature.  The results are great”.

One system is transported to each of the five treatment centers to share. This makes the system very affordable and increases access to superior care. During our visit, we found everyone in the TVROC to be high quality, dedicated professionals who care deeply about their patient's health.  And did I mention great results!  To learn more about the clinical studies on treating RCW breast cancer and Head & Neck cancers using hyperthermia, click the links.

Cancer is the leading cause of death in urban China, according to the World Health Organization GLOBALCAN study. Lung, stomach, liver, esophageal, and colorectal cancers make up the second largest cause of death in the country overall. With a population approaching 1.4 billion, you can see how important it is to find successful therapies to treat this disease.

To address cancer treatment in China, our CTO and Chief Scientist, Paul Turner, was invited to speak at a conference held at the Dailan #2 Hospital in the Liaoning province of China. Paul, along with our CEO Mark Falkowski, made the trip last week to participate in the discussion.

The event attracted clinicians and researchers interested in understanding how hyperthermia can improve outcomes and save lives.

The presentations included:

  • Deep Hyperthermia with Phased Array Methods and Clinical Application; Paul Turner – Pyrexar Medical
  • Hyperthermia Combined with Taxol in Malignant Ascites Treatment; Dr. Yingying Huang - Beijing Hospital Oncology Department
  • Hyperthermia Combined with Chemotherapy in Gastrointestinal Tumors Treatment; Dr. Li Ding - Beijing Hospital Oncology Department
  • Green Therapy in Oncology-Application of BSD-2000 Annular Phased Array Methods; Qing Zhang - Beijing Chinese Medicine Hospital

As a wrap up to this auspicious event, our host Orientech invited our small U.S. delegation to a beautiful meal featuring regional favorites. Not only did we leave making many new friends, but we also negotiated a purchase agreement for four BSD-2000 Deep Regional Hyperthermia systems with our new distribution partner Orientech.

orientech group

We hope our entrance into the Chinese market will help reduce the number of cancer fatalities.